At the news
? BEARISHIMPACT 6/10 424B5 filed Nov 19, 2026 at 16:07 ET
SELLAS Life Sciences Group priced a $150M underwritten public offering of 11,538,462 shares at $13.00 per share, a 27.6% discount to the prior day's $17.95 close. The offering follows positive Phase 3 REGAL trial results announced November 17, 2026 and Q3 2026 earnings reported November 12, 2026. Net proceeds of approximately $140.6M will fund clinical development and commercialization activities.
- 11,538,462 shares offered at $13.00 per share, a 27.6% discount to the $17.95 closing price on November 18, 2026
- Total offering size of $150,000,006; net proceeds of approximately $140.6M ($161.8M if underwriters exercise full option)
- Underwriters have a 30-day option to purchase up to an additional 1,730,769 shares
- Shares outstanding will increase from 203,527,833 to 215,066,295 (5.7% dilution), or 216,797,064 if option exercised (6.5% dilution)
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access